IONIS PHARMACEUTICALS INCIONS
| Dec 31,
2010 | Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -61 | -85 | -65 | -61 | -39 | -88 | -87 | -6 | 274 | 303 | -451 | -29 | -270 | -366 | -454 |
|---|
| Depreciation | 5 | 7 | 7 | 7 | 6 | 7 | 7 | 7 | 11 | 13 | 13 | 15 | 14 | 10 | 10 |
|---|
| Amortization of right-of-use operating lease assets | - | - | - | - | - | - | - | - | - | - | 2 | 2 | 5 | 10 | 10 |
|---|
| Amortization of other assets | - | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 | 2 | 3 | 2 |
|---|
| Amortization of premium (discount) on investments, net | - | - | - | - | - | -8 | -7 | -7 | 1 | 7 | -12 | -18 | -7 | 29 | 38 |
|---|
| Amortization of debt issuance costs | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 5 | 5 | 6 | 7 |
|---|
| The amount of royalty payments made during the period under a royalty purchase agreement. | - | - | - | - | - | - | - | - | - | - | - | - | - | 45 | 45 |
|---|
| Amount of interest expense using the effective interest rate method related to the sale of future royalties. | - | - | - | - | - | - | - | - | - | - | - | - | - | 68 | 73 |
|---|
| Stock-based compensation expense | 12 | 10 | 9 | 11 | 31 | 59 | 72 | 86 | 131 | 147 | 230 | 121 | 100 | 106 | 130 |
|---|
| Gain on early retirement of debt | - | - | -5 | - | -8 | - | -4 | - | - | -22 | - | -9 | - | 13 | - |
|---|
| Non-cash losses related to disposal of property, plant and equipment | - | - | - | - | - | - | - | - | - | - | - | - | -1 | -17 | -7 |
|---|
| Loss (gain) on sale of real estate assets | - | - | - | - | - | - | - | - | - | - | - | - | 150 | -0 | - |
|---|
| Loss on investments | - | - | - | - | - | - | - | - | - | - | - | 1 | -0 | -2 | -3 |
|---|
| Non-cash losses related to other assets | - | - | - | - | - | - | - | - | - | - | 2 | 3 | 2 | 2 | 3 |
|---|
| Contracts receivable | - | - | - | - | - | - | - | - | -48 | 48 | 13 | -14 | -36 | 72 | -6 |
|---|
| Inventories | -0 | 2 | 2 | 2 | -2 | 1 | 1 | 2 | -1 | 5 | 1 | 3 | -3 | 6 | 5 |
|---|
| Other current and long-term assets | 1 | -1 | -0 | 1 | 2 | 4 | -2 | 58 | 29 | 45 | 10 | 1 | 25 | 30 | 26 |
|---|
| Accounts payable | 1 | 1 | 1 | 0 | 5 | 9 | -11 | 2 | -1 | -16 | -3 | -6 | 1 | 8 | 16 |
|---|
| Income taxes | - | - | - | - | -4 | - | 1 | 0 | -1 | 32 | -31 | -1 | 6 | -4 | -2 |
|---|
| Accrued compensation | 0 | 2 | -1 | 4 | 0 | 4 | 8 | 1 | 4 | 8 | 28 | -27 | 10 | 19 | 2 |
|---|
| Accrued liabilities and other current liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | -6 | -43 |
|---|
| Deferred contract revenue | - | - | - | - | - | - | - | - | 494 | -119 | -76 | -83 | -71 | 14 | -157 |
|---|
| Net cash used in operating activities | -64 | -115 | - | - | - | - | - | 174 | 603 | 346 | 36 | 31 | -274 | -308 | -501 |
|---|
| Purchases of short-term investments | - | 371 | 218 | 426 | 392 | 493 | 301 | 878 | 1,795 | 1,947 | 1,570 | 1,124 | 1,486 | 1,771 | 1,853 |
|---|
| Proceeds from sale of short-term investments | - | 489 | 243 | 173 | 295 | 420 | 365 | 557 | 883 | 1,952 | 1,886 | 1,344 | 989 | 1,585 | 1,769 |
|---|
| Purchases of property, plant and equipment | 13 | 7 | 1 | 2 | 8 | 8 | 7 | 35 | 14 | 31 | 35 | 12 | 16 | 24 | 45 |
|---|
| Proceeds from sale of real estate assets | 0 | - | - | - | - | - | - | - | - | - | - | - | 254 | 0 | - |
|---|
| Acquisition of licenses and other assets, net | - | - | - | - | - | - | - | - | - | - | - | 6 | 4 | 4 | 5 |
|---|
| Net cash used in investing activities | 24 | 111 | - | - | - | - | - | -358 | -930 | -41 | 274 | 195 | -263 | -214 | -134 |
|---|
| Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases | 4 | 4 | 9 | 63 | 23 | 25 | - | 23 | 28 | 120 | 52 | 12 | 6 | 49 | 34 |
|---|
| Proceeds from issuance of common stock in public offering, net | - | - | - | 173 | - | - | - | 72 | - | - | - | - | - | - | 489 |
|---|
| Repayment of 0.125 percent convertible senior notes | - | - | - | - | - | - | - | - | - | - | - | 62 | - | - | 45 |
|---|
| Proceeds from issuance of convertible senior notes | - | - | 195 | - | - | - | - | - | - | 110 | - | - | - | - | - |
|---|
| 1.75 percent convertible senior notes issuance costs | - | - | - | - | - | - | - | - | - | 10 | - | - | - | - | - |
|---|
| The cash inflow from the sale of future royalties under a royalty purchase agreement. | - | - | - | - | - | - | - | - | - | - | - | - | - | 500 | - |
|---|
| The cash outflow paid to third parties for transaction costs in connection with a monetization transaction of future SPINRAZA and pelacarsen royalties the Company is entitled to under collaboration and licensing agreements. | - | - | - | - | - | - | - | - | - | - | - | - | - | 10 | - |
|---|
| The cash inflow from the transfer of legal ownership of two lots of undeveloped land to a real estate investor. | - | - | - | - | - | - | - | - | - | - | - | - | - | 32 | - |
|---|
| Principal payments on mortgage debt | - | - | - | - | - | - | - | - | - | - | - | - | 51 | 0 | 0 |
|---|
| Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options | - | - | - | - | - | - | - | - | - | 19 | 13 | 17 | 11 | - | - |
|---|
| Net cash provided by (used in) financing activities | 5 | -1 | - | - | - | - | - | 229 | 476 | 100 | -597 | 246 | -55 | 644 | 478 |
|---|
| Effects of exchange rates on cash | - | - | - | - | - | - | - | - | - | - | - | - | -0 | 0 | -0 |
|---|
| Net increase (decrease) in cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | -286 | 472 | -593 | 123 | -157 |
|---|
| Interest paid | 5 | - | - | - | - | - | - | 8 | 10 | 10 | 6 | 5 | 3 | 7 | 11 |
|---|
| Income taxes paid (refunds received) | 7 | 0 | 0 | 0 | - | - | - | - | - | 9 | 26 | - | - | - | -6 |
|---|
| Right-of-use assets obtained in exchange for lease liabilities | - | - | - | - | - | - | - | - | - | 14 | 2 | 7 | 169 | - | - |
|---|
| Future cash outflow to pay for purchases of fixed assets and patents that have occurred. | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
|---|